1 Min Read
* Cannimed Therapeutics Inc reports financial results for Q2 2017
* Qtrly revenue increased to $3.7 million from $2.2 million for comparable period in previous fiscal year
* Qtrly loss per share $0.08 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.